103 related articles for article (PubMed ID: 8156964)
1. Circadian carbamazepine toxicity.
Haefeli WE; Meyer PG; Lüscher TF
Epilepsia; 1994; 35(2):400-2. PubMed ID: 8156964
[TBL] [Abstract][Full Text] [Related]
2. Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations.
Eeg-Olofsson O; Nilsson HL; Tonnby B; Arvidsson J; Grahn PA; Gylje H; Larsson C; Norén L
J Child Neurol; 1990 Apr; 5(2):159-65. PubMed ID: 2111837
[TBL] [Abstract][Full Text] [Related]
3. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine.
Miller AD; Krauss GL; Hamzeh FM
Acta Neurol Scand; 2004 Jun; 109(6):374-7. PubMed ID: 15147458
[TBL] [Abstract][Full Text] [Related]
4. Developmental and therapeutic pharmacology of antiepileptic drugs.
Miura H
Epilepsia; 2000; 41 Suppl 9():2-6. PubMed ID: 11156504
[TBL] [Abstract][Full Text] [Related]
5. Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations.
Wolf P; May T; Tiska G; Schreiber G
Arzneimittelforschung; 1992 Mar; 42(3):284-8. PubMed ID: 1497685
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults.
Chien S; Bialer M; Solanki B; Verhaeghe T; Doose DR; Novak G; Yao C
Epilepsia; 2006 Nov; 47(11):1830-40. PubMed ID: 17116022
[TBL] [Abstract][Full Text] [Related]
7. Carbamazepine and its epoxide: an open study of efficacy and side effects after carbamazepine dose increment in refractory partial epilepsy.
Semah F; Gimenez F; Longer E; Laplane D; Thuillier A; Baulac M
Ther Drug Monit; 1994 Dec; 16(6):537-40. PubMed ID: 7878690
[TBL] [Abstract][Full Text] [Related]
8. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
Ahmad A; Garnett WR
Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654
[TBL] [Abstract][Full Text] [Related]
9. The metabolization of carbamazepine to CBZ-10,11-epoxide in children from the newborn age to adolescence.
Korinthenberg R; Haug C; Hannak D
Neuropediatrics; 1994 Aug; 25(4):214-6. PubMed ID: 7824094
[TBL] [Abstract][Full Text] [Related]
10. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.
Trinka E; Marson AG; Van Paesschen W; Kälviäinen R; Marovac J; Duncan B; Buyle S; Hallström Y; Hon P; Muscas GC; Newton M; Meencke HJ; Smith PE; Pohlmann-Eden B;
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1138-47. PubMed ID: 22933814
[TBL] [Abstract][Full Text] [Related]
11. Catastrophic neurologic signs due to drug interaction: Tegretol and Darvon.
Oles KS; Mirza W; Penry JK
Surg Neurol; 1989 Aug; 32(2):144-51. PubMed ID: 2749458
[TBL] [Abstract][Full Text] [Related]
12. Carbamazepine (CBZ) controlled release compared with conventional CBZ: a controlled study of attention and vigilance in children with epilepsy.
Pieters MS; Jennekens-Schinkel A; Stijnen T; Edelbroek PM; Brouwer OF; Liauw L; Heyer A; Lanser JB; Peters AC
Epilepsia; 1992; 33(6):1137-44. PubMed ID: 1464276
[TBL] [Abstract][Full Text] [Related]
13. Carbamazepine in comparative trials: pharmacokinetic characteristics too often forgotten.
Arroyo S; Sander JW
Neurology; 1999 Oct; 53(6):1170-4. PubMed ID: 10522867
[TBL] [Abstract][Full Text] [Related]
14. Rapid switchover to carbamazepine using pharmacokinetic parameters.
Kanner AM; Bourgeois BF; Hasegawa H; Hutson P
Epilepsia; 1998 Feb; 39(2):194-200. PubMed ID: 9578000
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy.
Garnett WR; Levy B; McLean AM; Zhang Y; Couch RA; Rudnic EM; Pellock JM; Belendiuk GW
Epilepsia; 1998 Mar; 39(3):274-9. PubMed ID: 9578044
[TBL] [Abstract][Full Text] [Related]
16. A single and multiple dose bioavailability study with carbamazepine 400 mg retard tablets with reference to enzyme autoinduction and circadian time differences.
Hoffmann C; Zschiesche M; Franke G; Hoffmann A; Terhaag B; Möritz KU; Siegmund W
Int J Clin Pharmacol Ther; 1997 Nov; 35(11):496-503. PubMed ID: 9401830
[TBL] [Abstract][Full Text] [Related]
17. Clinical feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy.
Lee SA; Heo K; Kim WJ; Song HK; Kim SE; Kim SH; No SK; Lee BI
Seizure; 2010 Jul; 19(6):356-8. PubMed ID: 20538492
[TBL] [Abstract][Full Text] [Related]
18. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?
Besag FM; Berry DJ; Pool F; Newbery JE; Subel B
Epilepsia; 1998 Feb; 39(2):183-7. PubMed ID: 9577998
[TBL] [Abstract][Full Text] [Related]
19. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.
Powell G; Saunders M; Marson AG
Cochrane Database Syst Rev; 2010 Jan; (1):CD007124. PubMed ID: 20091617
[TBL] [Abstract][Full Text] [Related]
20. Intravenous carbamazepine: a new formulation of a familiar drug.
Klein P; Tolbert D
Expert Rev Neurother; 2017 Sep; 17(9):851-860. PubMed ID: 28783998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
